资料发布时间:2018-10-30 14:50:00 最后更新时间: 2021-06-09 15:17:08
【药品简介】 色瑞替尼是晚期转移性非小细胞肺癌的一种小分子靶向药物,其相应的基因靶点是ALK,是肿瘤药物中专门针对ALK基因重排的有效药物。患者单次口服后约在4至6小时后血液中药物达到最高浓度。
【适应症状】 色瑞替尼,1)晚期非小细胞肺癌,ALK突变阳性 2)晚期非小细胞肺癌,ALK突变阳性,对克唑替尼耐药后的选择 3)晚期非小细胞肺癌,ALK突变阳性,对克唑替尼等药物产生严重副作用后的选择
【 药品别名 】 色瑞替尼 Ceritinib
印度色瑞替尼(色瑞替尼 Ceritinib)价格,正品图片,治疗肺癌药物, 购买色瑞替尼请到印度药房官方网站进行购买 【印度药房大全目录】
【 市场参考价格 】 ¥1228.00~1600.00
播放/暂停
生物活性
产品描述 |
Ceritinib (LDK378) is a specific ALK inhibitor (IC50: 0.2 nM). |
靶点活性 |
ALK,0.2 nM (cell free) FLT3,60nM IGF-1R,8 nM (cell free) Insulin Receptor,7 nM (cell free) STK22D,23 nM (cell free) |
体外活性 |
Ceritinib (LDK378) also inhibits RET (IC50: 400 nM), FGFR3 (IC50: 430 nM), LCK (IC50: 560 nM), JAK2 (IC50: 610 nM), Aurora (IC50: 660 nM), LYN (IC50: 840 nM), EGFR (IC50: 900 nM), and FGFR4 (IC50: 950 nM) [1]. In ALK-positive cell line models, ceritinib was able to effectively inhibit ALK harboring the crizotinib-resistant mutations L1196M, G1269A, I1171T, and S1206Y, but it was ineffective at inhibiting ALK containing the G1202R and F1174C mutations.49 Among a panel of 46 other tested kinases, ceritinib showed strong activity only against IGF-1R (IC50: 8 nM), INSR (IC50: 7 nM), and STK22D (IC50: 23 nM) [2]. |
体内活性 |
Mice treated with ceritinib at 50 mg/kg remained in complete remission with no discernible tumor growth for 4 months. In the mice treated with ceritinib at 25 mg/kg, tumor re-growth was observed in 4 out of 8 animals after 1 month, whereas complete remission was maintained in the other 4 animals for 4 months. In a primary explant model derived from a crizotinib-nave NSCLC tumor MGH006, treatment with 25 mg/kg ceritinib also led to tumor regressions [3]. |
激酶实验 |
All kinases were expressed as either Histidine- or GST-tagged fusion proteins using the baculovirus expression technology except for the untagged ERK2 which was produced in E. coli. The kinase activity was measured in the LabChip mobility-shift assay. The assay was performed at 30°C for 60 min. The effect of the compound on the enzymatic activity was obtained from the linear progress curves in the absence and presence of compound and routinely determined from one reading (end point measurement) [1]. |
细胞实验 |
Luciferase-expressing cells were incubated with serial dilutions of compounds or DMSO for 2–3 days. Luciferase expression was used as a measure of cell proliferation/survival and was evaluated with the Bright-Glo Luciferase Assay System. IC50 values were generated by using XLFit software [1]. 细胞系: Ba/F3-NPM-ALK, Ba/F3-Tel-InsR, Ba/F3-WT, Karpas299 cells |
动物实验 |
SCID beige mice for crizotinib-resistant H2228 xenograft tumor models, nude mice for MGH006 primary explants and MGH045 cells were randomized into groups of 5, 6 or 8 mice with an average tumor volume of ~150 mm^3 and received Crizotinib or ceritinib daily treatments by oral gavage as indicated in each study. Tumor volumes were determined by using caliper measurements and calculated with the formula (Length × Width × Height)/2 [3]. 动物模型:RNU nude rats bearing the Karpas299/H2228 tumors |
化学信息
分子量 |
558.14 |
分子式 |
C28H36ClN5O3S |
CAS |
1032900-25-6 |
溶解度 |
DMSO: 16 mg/mL (28.7 mM) Ethanol: 3 mg/mL (5.37 mM) Water: <1 mg/mL ( < 1 mg/ml refers to the product slightly soluble or insoluble ) |
储存条件 |
store at -80°C |
备注 |
For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. |
配制溶液
1 mg | 5 mg | 10 mg | |
1 mM | 1.792 ml | 8.958 ml | 17.917 ml |
5 mM | 0.358 ml | 1.792 ml | 3.583 ml |
10 mM | 0.179 ml | 0.896 ml | 1.792 ml |
50 mM | 0.036 ml | 0.179 ml | 0.358 ml |
【用法用量】 推荐用量: 1)甲状腺髓样癌:每次140mg,每日一次,轻度及中度肝损伤患者起始剂量为80mg 2)肾癌、......
【用法用量】 1)推荐剂量:2mg/day,口服,每日一次;在相同时间服用,直到疾病进展或出现不可耐受的毒性。 2)至少......
用法用量】 1)推荐剂量:每次450mg,每天一次,同食物一起服用;长期服用直至疾病出现新的进展或出现不可耐受的毒副作用......
【作用机制】 克唑替尼是一个酪氨酸激酶受体抑制剂,抑制间变性淋巴瘤激酶(ALK),肝细胞生长因子(HGFR,c-MET)......
作用机制: 奥希替尼是一个EGFR酪氨酸激酶抑制剂,不可逆的与特定的EGFR突变结合,包括T790M,L858R和19号......
不良反应: 鳞癌患者(有转移):用于含铂方案化疗肿瘤继续进展者。 作用机制: 高选择性ErbB抑制剂,不可逆的结合酪氨酸......
【给药方法】 每天一次,空腹服用(饭前一小时或饭后2小时) 厄洛替尼单药用于非小细胞肺癌的推荐剂量为150mg/日,至少......
【作用机制】 吉非替尼是一个酪氨酸激酶抑制剂(TKI),可逆性的抑制特定类型的EGFR突变。EGFR(表皮生长因子受体)......
肺癌是严重危害患者生命的疾病,一旦发生后,患者都会非常担忧和害怕。肺癌需要积极乐观面对,要配合医生使用药物治疗。色瑞替尼......
作为一种靶向抗癌药物,色瑞替尼是一种具有靶向能力的药物或制剂,能使药物其载体能标准特定的病变部位。可以使药物在靶点形成相......
克唑替尼是一种新型的间变性淋巴瘤激酶(ALK)/间充质上皮生长因子(c-MET)/肝细胞生长因子受体(HGFR)激酶小分......
吉非替尼作为一种EGFR抑制剂,其作用机制主要是通过抑制EGFR自身磷酸化来阻断传导和抑制肿瘤细胞增殖,从而实现肺癌患者......
尽管色瑞替尼的价格非常昂贵,但大多数患者在充分利用搜索和详细了解替代疗法后,仍然可以找到与药物效果相同的印度色瑞替尼。你......
预防肺癌的方法为远离五气,大气污染属于政府行为,其他四气可由自己掌控,包括戒烟、绿色装修...
Pharmacy Catalogue
【代购】【有实体店】【在线客服懂中文】
代购+直邮,印度抗癌药跨境医药电商直邮服务,让肿瘤患者能够有更好的选择,平台提供印度就医,印度易瑞沙,吉三代,吉二代,索......
【禁止中国访问 】【印度连锁】【品牌实力】
MedPlus是印度第二大药房连锁店。它经营1555家商店,其中1317家为公司所有,159家为特许经营公司,43家为医......
【药品种类丰富 】【渠道正规】【价格较高】
Wellness Forever是一家生活方式零售药房连锁店,致力于为印度本土客户提供全面的健康服务。目前总收入约为62......
【visa/万事达】 【全球可邮 】【纯线上销售】【可开处方】
Netmeds.com致力于开发印度本土市场,已成为印度领先的在线药店。Netmeds.com通过其全天候在线门户和移动......